Best Life Sciences Platforms and Tools Companies in Japan
The 136 best Life Sciences Platforms and Tools companies in Japan in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: PHC Holdings.
Japan's Life Sciences Platforms and Tools sector is exactly what this directory maps: 136 companies ranked by disclosed equity funding and recent momentum, with PHC Holdings leading the pack at $182M raised and ThinkCyte not far behind at $83M.
The full $515M in tracked funding across those 136 companies tells one story, but the spread tells another. Most companies here are early-stage, zero unicorns, and the gap between PHC Holdings and the next tier, think Orizuru Therapeutics at $22M, is wide enough to notice. That's not a weakness, it's a structural feature of Japan's life sciences build-out right now. The global market these companies are chasing sat at roughly $89.4B in 2020 and is forecast to reach $183.8B by 2027 at a 10.8% CAGR, driven by advances in quantitative accuracy, mass spec resolution, and information sciences. Regulatory friction is real, and you'll want to factor that into any diligence here. So the opportunity is large, the capital is concentrated, and investors like Mitsubishi UFJ Capital and SBI Investment are the ones placing the early bets. I'd watch how the mid-tier cohort closes that funding gap over the next few quarters.
- Precedence Research
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in Japan
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PHC Holdings Provider of devices and services for life science research | $182M | 62 mo ago | 3 | Shoji Miyazaki Co-CEO | StoryblokNode.jsTailwind CSS+20 | Top 500k | 1,049 patents Patents concentrated in computing, sensing & instrumentation | 1 job opening · 5 launchs |
| 2 | Atonarp Developer of spectrometry platforms for industrial process control, life science research | $111M | 61 mo ago | 74 | Tomoyashi Sato Co-Founder | WebflowMarkerZoho+21 | Top 10M | 326 patents Gas analysis and laser spectroscopy instrumentation for fluid and plasma diagnostics | — |
| 3 | ThinkCyte Developer of cell sorting and single cell profiling platforms | $83M | 21 mo ago | 33 | Ryoichi Horisaki Co-Founder | WordPressMySQLPHP+28 | Top 5M | 95 patents Advanced flow cytometry and AI-driven cellular sample analysis technologies. | 3 launchs |
| 4 | Orizuru Therapeutics Developer of stem-cell-derived organoid models for drug discovery | $22M | 27 mo ago | 60 | Kenji Nonaka CEO | WordPressApple iCloud MailMicrosoft 365+12 | Top 5M | 98 patents Regenerative cell therapies and tissue-engineered constructs for cardiac and stem cell applications | — |
| 5 | Cyfuse Developer of 3D tissue engineering technology | $17M | 135 mo ago | 22 | Shizuka Akieda CEO | WordPressMySQLPHP+14 | Top 5M | — | — |
| 6 | Molcure Provider of AI-based platform for drug discovery and design | $12M | 58 mo ago | 33 | Yutaro Kyono Co-Founder & CTO | — | — | 10 patents Protein‑binding assay technologies and bubble‑generation systems for drug delivery | — |
| 7 | OriCiro Genomics Developer of technologies for DNA synthesis and amplification | $11M | 48 mo ago | 10 | — | — | — | 47 patents Cell‑free DNA synthesis, circular DNA production, and enzymatic DNA editing/assembly technologies. | — |
| 8 | GlyTech Provider of human-type asparagine (Asp)-linked glycans for research applications | $9M | 53 mo ago | 6 | Hiroaki Asai CEO | — | — | 342 patents Peptide-based ocular therapeutics and protein engineering for solubility, antibodies, and KRAS targeting | — |
| 9 | CellSeed cell culture consumable | $7M | 144 mo ago | 44 | — | Pure CSSNginxjQuery+6 | Top 5M | 166 patents Regenerative cell sheet technology for cartilage and tissue repair | — |
| 10 | Repertoire TCR/BCR repertoire analysis services | $6M | 118 mo ago | 20 | Ryuji Suzuki CEO & President | — | — | — | — |
| 11 | Braizon Therapeutics Developer of drug delivery technology for CNS disorders | $6M | 94 mo ago | 1 | Mariko Toji CEO | WordPressMySQLPHP+11 | Top 10M | — | — |
| 12 | PuREC Developer of stem cell technologies | $6M | 50 mo ago | 5 | Kobayashi Yoshiyasu CEO & President | WordPressMySQLPHP+17 | Top 50M | 45 patents Patents concentrated in chemistry & materials | — |
| 13 | CellFiber Provider of cell fiber technology based solutions | $6M | 31 mo ago | 7 | Aki Adachi Founder | — | — | 38 patents Cell encapsulation, hydrogel production, and fiber-based cell culture manufacturing technologies. | 1 launch |
| 14 | TAGCyx Provider of nucleic acid-based drug discovery platform | $5M | 59 mo ago | 18 | — | WordPressMySQLPHP+13 | Top 10M | — | — |
| 15 | Digzyme Digital molecular modelling tool for drug development | $5M | 25 mo ago | — | Takuji Yamada Co-Founder | — | — | — | — |
| 16 | KAICO Manufacturer of portfolio of proteins and other biological cytokines and enzymes | $4M | 14 mo ago | 10 | Kenta Yamato CEO | WordPressMySQLPHP+17 | Top 10M | 17 patents Oral vaccine formulations for mucosal immunization and delivery | — |
| 17 | Synplogen Developer of technology for DNA synthesis | $4M | 16 mo ago | — | Junichi Sugahara CEO | — | — | 62 patents Engineered nucleic acid vectors and plasmids for enhanced protein expression and production | — |
| 18 | CYBO Developer of cell cytometry and cell sorting platforms for life science experts | $3M | 36 mo ago | 8 | — | microCMSNode.jsThree.js+12 | Top 50M | 23 patents Microscopy slide handling hardware and image analysis/display software for scientific imaging | 1 award |
| 19 | Platinum Bio Developer of gene editing technology | $3M | 32 mo ago | 12 | Takashi Yamamoto Co-Founder | Wix eCommerceWixSentry+12 | Top 50M | — | 1 launch · 1 expansion · 1 award |
| 20 | OMR Developer of antibodies for the treatment of various diseases | $3M | 110 mo ago | 12 | Yasufumi Murakami Founder | — | — | — | — |
| 21 | Gel Coat Biomaterials Developer of hydrogel technology related to biomaterials and medical applications | $3M | 1 mo ago | — | Shin Yoshida Co-Founder & CEO | — | — | — | — |
| 22 | Veneno Technologies Developer of high-throughput screening technology-based drug discovery platform | $2M | 49 mo ago | 3 | Kazunori Yoshikawa CEO | — | — | — | — |
| 23 | Chromocenter Tools for cell line development | $2M | 118 mo ago | 10 | — | — | — | 5 patents Chromosome engineering tools for artificial chromosomes, gene amplification, and cytogenetic diagnostics | — |
| 24 | On-chip Biotechnologies Developer of cell sorters based on microfluidic chip technology | $1M | 25 mo ago | — | Masayuki Kobayashi President & CEO | — | — | 73 patents Microfluidic chips for single‑particle detection, sorting, and analysis in biomedical assays | — |
| 25 | BioPhenoMA Developer of microfluidic devices for the detection of ultra-trace proteins | $1M | 19 mo ago | — | Etsuro Ito Co-Founder | Wix eCommerceWixSentry+12 | Top 50M | 4 patents Patents concentrated in chemistry & materials | — |
| 26 | Myoridge Specializes in cell line development | $1M | 110 mo ago | — | Shinichi Sueda Co-Founder | — | — | 25 patents Manufacturing and assaying human cardiomyocytes and T‑cells using serum‑free culture systems | — |
| 27 | HikariQ Developer of immunoassays and antibody drugs | $616K | 40 mo ago | — | Kosuke Yoshii CEO | — | — | — | — |
| 28 | ReproCELL Leading global supplier of iPS-derived cells, stem cell reagents, human biofluids, and 3D cell culture. | $293K | 79 mo ago | 123 | — | HubSpot CMS HubGSAPSwiper+13 | Top 5M | 43 patents Patents concentrated in chemistry & materials | 1 award |
| 29 | MicroBiopharm Japan Provides discovery and contract research services to the biopharma companies | $124K | 185 mo ago | 344 | Suzuki Masan CEO | Apple iCloud MailMicrosoft 365Apache HTTP Server+1 | Top 10M | 71 patents Enzymatic synthesis of maytansinol and related ADC payloads; production of antibody‑drug conjugates | — |
Top 12 Life Sciences Platforms and Tools companies in Japan
#1
Seed · Chiyoda City, Tokyo · founded 2024$2.6Mraised▾
Developer of hydrogel technology related to biomaterials and medical applications. The company specializes in developing bio-materials using Ameba Hydrogel technology for environmental, chemical, and medical applications based on life science and bioengineering.
- Apr 2026Seed$1.3M
- Feb 2024Seed$1.3M
#2
Series C · Bunkyo, Tokyo · founded 2016 · 33 employees$83.2Mraised▾
Developer of cell sorting and single cell profiling platforms. The business provides tools for cell therapy, disease profiling, and drug discovery applications. The platforms combine fluorescence flow cytometry with morphological profiling and artificial intelligence. The business also offers related consumables and instrument services.
- Aug 2024Series C$14.9M
- Nov 2023Series C$24M
- Nov 2023Grant (prize money)—
- May 2021Series B$26M
#3
Series B · Fukuoka, Fukuoka · founded 2018 · 10 employees$4.4Mraised▾
Manufacturer of a portfolio of proteins and other biological cytokines and enzymes. The product is used for medicine, diagnostic agents and reagents. The company has its flagship technology for the silkworm-baculovirus expression system for protein. It also offers contract research services for protein expression and other products like PNGase-F, bFGF, NucA, and others.
- Apr 2025Series B$3.8M
- Jan 2024Series A$2M
- Dec 2021Series A—
- May 2020Series A$2.4M
#4
Series D · Tsuruoka, Yamagata · founded 2017$3.8Mraised▾
Developer of technology for DNA synthesis. It offers its flagship technology OGAB which is a used to synthesize 50 DNA at once utilizing Bacillus subtilis and Combi-OGCB for the synthesis of the cluster of genes from microbes. It offers its services of long-chain DNA synthesis, DNA library synthesis, and microbial-based production for genetic engineering approaches to different medical, biotechnological and food industries.
- Jan 2025Series D$3.8M
- Feb 2023Series C—
- Nov 2021Seed—
- May 2019Seed—
#5
Series B · Kyoto, Kyoto · founded 2021 · 60 employees$21.9Mraised▾
Developer of stem-cell-derived organoid models for drug discovery. The company has developed products such as regenerative medicine by cell transplantation and IPS-derived tissue models for drug discovery. It has developed iPS cell-derived cardiomyocytes for cardiac drug discovery and iPS cell-derived islet cells (iPIC) which applies to cell therapy for diabetes.
- Feb 2024Series B$21.9M
#6
Public · Tokyo, Tokyo · founded 1969 · 3 employees$182.3Mraised▾
Provider of devices and services for life science research. It is developing test analysis devices, healthcare IT solutions, and instruments for the life sciences industry. It also provides drug delivery solutions and medical record systems.
#7
Series D · Minato City, Tokyo · founded 2009 · 74 employees$111Mraised▾
Developer of spectrometry platforms for industrial process control, life science research. The company’s platforms harness spectrometry technologies with advanced analytics to generate actionable results. These platforms apply to applications across multiple industries. The company offers in-situ metrology for semiconductor manufacturing and multiplex testing.
- May 2021Series D$50M
- Aug 2019Series C$33M
- Jul 2016Series B$16M
- Aug 2014Series A$8M
#8
Seed · Shinjuku City, Tokyo · founded 2023$1.2Mraised▾
Developer of microfluidic devices for the detection of ultra-trace proteins. The company is working on the development of a compact benchtop detection system using microfluidic device that can detect ultra-trace proteins by utilizing the "TN-cyclon"(improved enzymatic cycling method).
- Nov 2024Seed$1.2M
#9
Series A · Minato City, Tokyo · founded 2019$4.7Mraised▾
Digital molecular modelling tool for drug development. The company has developed a platform that assists in calculating compound structures, enzymatic reactions, and more. It also has features for enzyme screening, bio-retrosynthesis and more.
- Apr 2024Series A$4.7M
#10
Series A · Bunkyo, Tokyo · founded 2015 · 7 employees$5.5Mraised▾
Cellfiber is a provider of cell fiber technology-based solutions. Cells processed into a fiber can be treated as a standardized fibrous part and can be assembled into various structures using living cells. The company is developing this technology to increase the efficiency of cell cultures and to create artificial biomaterials.
- Nov 2023Series A$5.5M
#11
Acquired · Tokyo, Tokyo · founded 2018 · 10 employees$10.9Mraised▾
Developer of technologies for DNA synthesis and amplification. The company has an OriCiro Cell-Free Cloning System which is composed of OriCiro Assembly Kit and OriCiro Amp Kit that enables cell-free assembly and amplification of circular DNA molecules.
- Jun 2022Series B—
- Jul 2021Series B$7.3M
- Jul 2021Conventional Debt$1.8M
- Apr 2019Series A$3.6M
#12
Series A · Hiroshima, Hiroshima · founded 2019 · 12 employees$3.3Mraised▾
pt-bio is developing gene-editing technology. It provides multiple services such as genome editing technology, genome consulting technology, and provides genome editing databases among others.
- Sep 2023Series A$3.3M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in Japan
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,330 Japan-affiliated papers.
- The University of Tokyo147
- Kyoto University82
- Korea University65
- The University of Osaka59
- Keio University43
- Gene5→74
- Genome9→76
- Identification (biology)2→31
- Immune system1→25
- Disease1→24
- Gene1→32
- Transcriptome1→24
- Cancer3→20
- Identification (biology)1→9
- microRNA1→8
- Genome1→11
- Mechanism (biology)1→7
- Gene1→4
Where bioinformatics is researched across Japan
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.